The phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial found the addition of tumor treating fields (TTFields) to paclitaxel did not provide a statistically significant ...
The phase 3 LUNAR trial evaluating tumor treating fields (TTFields) with standard-of-care therapies met its primary end point in patients with metastatic non–small cell lung cancer (NSCLC). In the ...
TRIDENT is a global, open-label, two-arm trial; secondary end points include progression-free survival, overall radiologic ...
(HealthDay)—For patients with glioblastoma, the addition of tumor-treating fields (TTFields) to standard treatment with temozolomide is associated with improved survival without negative effects on ...
SAN FRANCISCO — Tumor-treating fields (TTFields, Novocure) therapy, already approved for use in glioblastoma, has now shown benefit in patients with advanced pancreatic cancer. TTFields combined with ...
The MarketWatch News Department was not involved in the creation of this content. METIS trial achieved its primary endpoint, showing a statistically significant delay in time to intracranial ...
Novocure Limited NVCR announced meeting the primary endpoint of overall survival (OS) in a late-stage study, which evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with ...
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on ...
CHICAGO -- Treatment with tumor treating field (TTFields) therapy combined with standard of care improved overall survival versus standard of care alone in patients with metastatic non-small cell lung ...
Tumor-treating fields (TTFields) use electric fields tuned to specific frequencies to disrupt the division of solid tumor cancer cells. Novocure has launched Optune, its first TTFields delivery system ...
Novocure (NASDAQ: NVCR) announced today results from the second cohort of its phase 2 pilot PANOVA trial studying Tumor Treating Fields (TTFields) in combination with nab-paclitaxel and gemcitabine ...
Glioblastoma is the most common and aggressive form of primary brain tumour, with median overall survival durations in clinical trials of <17 months emphasizing the need for more effective therapy. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results